KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Clover Health Investments (CLOV) Shares Outstanding (Diluted Average) (2019 - 2025)

Clover Health Investments' Shares Outstanding (Diluted Average) history spans 7 years, with the latest figure at $512.0 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Diluted Average) rose 4.48% year-over-year to $512.0 million; the TTM value through Dec 2025 reached $512.0 million, up 4.48%, while the annual FY2025 figure was $512.0 million, 4.48% up from the prior year.
  • Shares Outstanding (Diluted Average) reached $512.0 million in Q4 2025 per CLOV's latest filing, roughly flat from $510.2 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $512.0 million in Q4 2025 to a low of $376.2 million in Q1 2021.
  • Average Shares Outstanding (Diluted Average) over 5 years is $470.9 million, with a median of $480.3 million recorded in 2023.
  • Peak YoY movement for Shares Outstanding (Diluted Average): skyrocketed 365.57% in 2021, then rose 0.64% in 2023.
  • A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $412.9 million in 2021, then increased by 15.34% to $476.2 million in 2022, then rose by 1.25% to $482.2 million in 2023, then increased by 1.63% to $490.0 million in 2024, then grew by 4.48% to $512.0 million in 2025.
  • Per Business Quant, the three most recent readings for CLOV's Shares Outstanding (Diluted Average) are $512.0 million (Q4 2025), $510.2 million (Q3 2025), and $508.9 million (Q2 2025).